--- title: "Dogwood Therapeutics (DWTX) news: convertible notes" url: "https://aibio.space/companies/dogwood-therapeutics/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "DWTX convertible notes news: Dogwood Therapeutics exchanges $19.5 million Conjoint loan for preferred stock. Dogwood Therapeutics, Inc." --- DWTX Dogwood Therapeutics, Inc. NASDAQ · United States # Dogwood Therapeutics (DWTX) news DWTX convertible notes news Financings · 2026-10-19 ## [Dogwood Therapeutics agrees to sell $5 million of stock to top holder CK Life Sciences](https://aibio.space/news/dogwood-therapeutics-agrees-sell-5-million-stock-top-holder-ck-life/) Dogwood will issue 4,098,360 shares at $1.22 each, with no warrants, in a deal expected to close by October 29, 2026. The company says the proceeds extend its runway through March 2027, after cash of $9.6 million at June 30, 2026. ## Latest Dogwood Therapeutics news 1. 2026-08-13 Company Updates [Dogwood reports second quarter 2026 results and Halneuron update](https://aibio.space/news/dogwood-reports-second-quarter-2026-results-halneuron-update/) Dogwood reported a second quarter net loss of $11.5 million, including a $6.7 million non-cash impairment, and $9.6 million in cash that it says funds operations through the Phase 2b readout. 2. 2026-05-14 Company Updates [Dogwood reports first quarter 2026 results and SP16 IND approval](https://aibio.space/news/dogwood-reports-first-quarter-2026-results-sp16-ind-approval/) Dogwood reported a first quarter net loss of $5.0 million and cash on hand of $13.2 million, which it says runs into the fourth quarter of 2026. 3. 2025-04-03 Listings [Dogwood Therapeutics says it has regained Nasdaq stockholders' equity compliance](https://aibio.space/news/dogwood-therapeutics-says-has-regained-nasdaq-stockholders-equity/) Dogwood says a $19.9 million debt exchange with Conjoint and a sale of about $4.8 million in common stock lifted its stockholders' equity above the $2.5 million minimum. Nasdaq had set a May 14, 2025 deadline, and the release does not include a Nasdaq decision. 4. 2025-03-12 Financings [Dogwood Therapeutics exchanges $19.5 million Conjoint loan for preferred stock](https://aibio.space/news/dogwood-therapeutics-exchanges-19-5-million-conjoint-loan-preferred/) Dogwood will cancel its loans from Conjoint Inc., a subsidiary of its largest shareholder, for 284.2638 shares of Series A-1 preferred stock convertible into 10,000 common shares each. ## Dogwood Therapeutics at a glance - **Ticker**: DWTX - **Listing**: NASDAQ - **Country**: United States - **Cash, Jun 30, 2026**: $9.6 million ### Related companies - [Palisade Bio](https://aibio.space/companies/palisade-bio/) NASDAQ: PALI - [Connect Biopharma Holdings](https://aibio.space/companies/connect-biopharma/) NASDAQ: CNTB - [OnKure Therapeutics](https://aibio.space/companies/onkure-therapeutics/) NASDAQ: OKUR - [Emergent BioSolutions](https://aibio.space/companies/emergent-biosolutions/) NYSE: EBS - [ABVC BioPharma](https://aibio.space/companies/abvc-biopharma/) NASDAQ: ABVC - [Alpha Teknova](https://aibio.space/companies/alpha-teknova/) NASDAQ: TKNO - [Seaport Therapeutics](https://aibio.space/companies/seaport-therapeutics/) NASDAQ: SPTX - [Scorpius Holdings](https://aibio.space/companies/scorpius/) OTC: SCPX ### Also on NASDAQ - [Celldex Therapeutics](https://aibio.space/companies/celldex-therapeutics/) CLDX - [Exelixis](https://aibio.space/companies/exelixis/) EXEL - [Equillium](https://aibio.space/companies/equillium/) EQ - [CVRx](https://aibio.space/companies/cvrx/) CVRX - [Instil Bio](https://aibio.space/companies/instil-bio/) TIL - [Immuneering](https://aibio.space/companies/immuneering/) IMRX ## Dogwood Therapeutics annual financials | Line | FY2025 | FY2024 | |---|---|---| | Research and development | [$21.9 million](https://www.sec.gov/Archives/edgar/data/1818844/000110465926031061/) | [$3.5 million](https://www.sec.gov/Archives/edgar/data/1818844/000110465926031061/) | | Net income (loss) | [-$34.3 million](https://www.sec.gov/Archives/edgar/data/1818844/000110465926031061/) | [-$12.3 million](https://www.sec.gov/Archives/edgar/data/1818844/000110465926031061/) | | Cash from operations | [-$15.6 million](https://www.sec.gov/Archives/edgar/data/1818844/000110465926031061/) | [-$8.8 million](https://www.sec.gov/Archives/edgar/data/1818844/000110465926031061/) | | Cash and equivalents | [$6.5 million](https://www.sec.gov/Archives/edgar/data/1818844/000110465926096719/) | [$14.8 million](https://www.sec.gov/Archives/edgar/data/1818844/000110465926031061/) | Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $9.6 million. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about Dogwood Therapeutics Has Dogwood Therapeutics sold convertible notes? Our latest story on this, dated Mar 12, 2025: "Dogwood Therapeutics exchanges $19.5 million Conjoint loan for preferred stock". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/dogwood-therapeutics-exchanges-19-5-million-conjoint-loan-preferred/). What is the ticker symbol of Dogwood Therapeutics? Dogwood Therapeutics, Inc. trades under the ticker DWTX on NASDAQ. Where is Dogwood Therapeutics listed? Dogwood Therapeutics, Inc. is listed on NASDAQ. What is the SEC CIK of Dogwood Therapeutics? The SEC Central Index Key (CIK) for Dogwood Therapeutics, Inc. is 1818844. Its filings are on SEC EDGAR. How many shares does Dogwood Therapeutics have outstanding? 33,992,553 shares as of 2026-08-13, per the cover page of its 10-Q filed 2026-08-14. Which country or territory is Dogwood Therapeutics listed under? Our directory records Dogwood Therapeutics, Inc. under United States. What does Dogwood Therapeutics do? Our directory classifies Dogwood Therapeutics, Inc. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline. What is the ISIN of Dogwood Therapeutics? The ISIN recorded for Dogwood Therapeutics, Inc. is US92829J2033. Does aibio.space cover Dogwood Therapeutics? aibio.space lists Dogwood Therapeutics, Inc. among 2,820 public biotech companies and publishes its news here as stories appear. Where is Dogwood Therapeutics incorporated? SEC records list its state or country of incorporation as DE. Is Dogwood Therapeutics profitable? Dogwood Therapeutics, Inc. reported a net loss of $34.3 million for the fiscal year ended Dec 31, 2025, and used $15.6 million of cash in operations, per its annual report to the SEC. How much does Dogwood Therapeutics spend on research and development? $21.9 million in the fiscal year ended Dec 31, 2025, per its annual report. How much cash does Dogwood Therapeutics have? $9.6 million in cash at Jun 30, 2026, per its 10-Q. What is the latest Dogwood Therapeutics (DWTX) stock news? Our latest story on Dogwood Therapeutics, dated Oct 19, 2026: "Dogwood Therapeutics agrees to sell $5 million of stock to top holder CK Life Sciences". Dogwood will issue 4,098,360 shares at $1.22 each, with no warrants, in a deal expected to close by October 29, 2026. The company says the proceeds extend its runway through March 2027, after cash of $9.6 million at June 30, 2026. [Source](https://aibio.space/news/dogwood-therapeutics-agrees-sell-5-million-stock-top-holder-ck-life/). What is Dogwood Therapeutics's latest stock offering or financing news? Our latest financing story, dated Oct 19, 2026: "Dogwood Therapeutics agrees to sell $5 million of stock to top holder CK Life Sciences". Dogwood will issue 4,098,360 shares at $1.22 each, with no warrants, in a deal expected to close by October 29, 2026. The company says the proceeds extend its runway through March 2027, after cash of $9.6 million at June 30, 2026. [Source](https://aibio.space/news/dogwood-therapeutics-agrees-sell-5-million-stock-top-holder-ck-life/). ## Investor discussion: Dogwood Therapeutics Members talk about Dogwood Therapeutics (DWTX). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at Dogwood Therapeutics, newest first. Each line links the filing it comes from. 1. 2026-10-19 Financings Reported a financing. SEC Form 8-K (Items 1.01,3.02,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1818844/000110465926116748/dwtx-ex99d1.htm) 2. 2026-01-13 Financings Reported a financing. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/1818844/000110465926003197/tm262999d1_424b5.htm) 3. 2025-11-28 Financings Reported a financing. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/1818844/000110465925116859/tm2532374d1_424b5.htm) 4. 2025-09-29 Financings Reported an unregistered sale of its securities. SEC Form 8-K (Items 1.01,3.02,3.03,5.03,7.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1818844/000110465925094109/dwtx-20250929xex99d1.htm) 5. 2025-06-24 Listings Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.02,5.07,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1818844/000155837025008817/dwtx-20250618x8k.htm) 6. 2025-04-03 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1818844/000155837025004362/dwtx-20250403xex99d1.htm) 7. 2025-03-14 Financings Reported a financing. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/1818844/000110465925023807/tm259202d1_424b5.htm) 8. 2025-03-12 Listings Reported a reverse stock split. SEC Form 8-K (Items 1.01,3.02,3.03,5.03,7.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1818844/000155837025002750/dwtx-20250312xex99d1.htm) 9. 2024-11-21 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). [Source](https://www.sec.gov/Archives/edgar/data/1818844/000155837024015884/dwtx-20241115x8k.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:DWTX on TradingView](https://www.tradingview.com/symbols/NASDAQ-DWTX/). ## SEC filings and registration - **SEC name**: Dogwood Therapeutics, Inc. - **CIK**: 1818844 - **Industry (SIC)**: Pharmaceutical Preparations (2834) - **US tickers**: DWTX (Nasdaq) - **State or country of incorporation**: DE - **Fiscal year ends**: December 31 - **Filer category**: Non-accelerated filer
Smaller reporting company - **Business address**: 44 MILTON AVENUE, ALPHARETTA, GA, 30009 - **Phone**: 8666208655 - **Shares outstanding**: 33,992,553 as of 2026-08-13 (10-Q filed 2026-08-14) - **Former names**: Virios Therapeutics, Inc.; Virios Therapeutics, LLC ### Recent filings (8-K and 6-K are the company's own announcements) - [8-K](https://www.sec.gov/Archives/edgar/data/1818844/000110465926116748/dwtx-20261019x8k.htm) filed 2026-10-19 - [10-Q](https://www.sec.gov/Archives/edgar/data/1818844/000110465926096719/dwtx-20260630x10q.htm) filed 2026-08-14 - [8-K](https://www.sec.gov/Archives/edgar/data/1818844/000110465926095512/dwtx-20260813x8k.htm) filed 2026-08-13 - [8-K](https://www.sec.gov/Archives/edgar/data/1818844/000110465926075204/dwtx-20260616x8k.htm) filed 2026-06-17 - [10-Q](https://www.sec.gov/Archives/edgar/data/1818844/000110465926061938/dwtx-20260331x10q.htm) filed 2026-05-15 - [8-K](https://www.sec.gov/Archives/edgar/data/1818844/000110465926060747/dwtx-20260514x8k.htm) filed 2026-05-14 - [DEF 14A](https://www.sec.gov/Archives/edgar/data/1818844/000110465926049277/dwtx-20260616xdef14a.htm) filed 2026-04-27 - [8-K](https://www.sec.gov/Archives/edgar/data/1818844/000110465926034928/dwtx-20260326x8k.htm) filed 2026-03-26 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001818844), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. ## Listing details Dogwood Therapeutics, Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker DWTX, recorded under United States. The directory classifies it as Pharmaceuticals: Major. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: Dogwood Therapeutics, Inc. - **Ticker**: DWTX - **Listing**: NASDAQ - **Country or territory**: United States - **Business scope**: Pharmaceuticals: Major - **ISIN**: US92829J2033 - **Last quote in directory**: 2026-10-21 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/NASDAQ-DWTX/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/dogwood-therapeutics/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Dogwood Therapeutics (DWTX) news: convertible notes", 2026-10-31, https://aibio.space/companies/dogwood-therapeutics/